Hutchison MediPharma Limited Announces Presentations of Sulfatinib and Fruquintinib Clinical Data at the 2012 ASCO Annual Meeting // Chi-Med
AIM: £45.10 (+0.35) | Nasdaq: $28.58 (-1.13)
News Archive
Previous Article   |   Next Article
Innovation Platform, RNS Announcements | 6 Jun 2012

Hutchison MediPharma Limited Announces Presentations of Sulfatinib and Fruquintinib Clinical Data at the 2012 ASCO Annual Meeting

1 Item
View Announcement (PDF)